Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2019

01-11-2019 | Acute Myeloid Leukemia | Original Article

Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia

Authors: Masahiro Sakaguchi, Hiroki Yamaguchi, Marika Kuboyama, Yuho Najima, Kensuke Usuki, Toshimitsu Ueki, Iekuni Oh, Shinichiro Mori, Eri Kawata, Nobuhiko Uoshima, Yutaka Kobayashi, Shinichi Kako, Kenji Tajika, Katsuhiro Shono, Kensuke Kayamori, Masao Hagihara, Junya Kanda, Hitoji Uchiyama, Junya Kuroda, Naoyuki Uchida, Yasushi Kubota, Shinya Kimura, Saiko Kurosawa, Kenta Date, Nana Nakajima, Atsushi Marumo, Ikuko Omori, Yusuke Fujiwara, Kazuki Terada, Shunsuke Yui, Satoshi Wakita, Kunihito Arai, Tomoaki Kitano, Kazuhiko Kakihana, Yoshinobu Kanda, Kazuteru Ohashi, Takahiro Fukuda, Koiti Inokuchi

Published in: International Journal of Hematology | Issue 5/2019

Login to get access

Abstract

The prognostic significance of FLT3-tyrosine kinase domain (TKD) mutations remains unknown. To investigate the prognostic impact of FLT3-TKD, 676 de novo acute myeloid leukemia (AML), we retrospectively analyzed cases and conducted a review of the literature. Of the 676 de novo AML cases, 34 (5.0%) were FLT3-TKD-positive; both FLT3-TKD and FLT3-ITD were noted in only two cases (0.3%). Although no significant differences in relapse-free survival (RFS) were noted, FLT3-TKD-positive cases showed better prognoses than FLT3-ITD-positive cases (FLT3-TKD versus FLT3-ITD, p = 0.152). For overall survival (OS), although FLT3-TKD-positive cases showed prognoses similar to those for FLT3-WT cases, their prognoses were significantly better than those of FLT3-ITD-positive cases (FLT3-TKD versus FLT3-ITD, p = 0.032). Moreover, the 5-year OS for FLT3-TKD-positive cases was 46.1%, indicating that this as an intermediate prognosis group. Although no reports from Asia have indicated a frequency of FLT3-TKD-positive cases > 10%, several reports from Europe and the United States have indicated frequencies > 10%. This suggests the possibility that FLT3-TKD-positive cases are less common in Asia than in Europe and the United States. We anticipate that in the future, the appearance of targeting agents, such as FLT3 inhibitors, will improve the prognosis of FLT3-TKD-positive AML relative to that of FLT3-WT AML.
Appendix
Available only for authorised users
Literature
1.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood. 2011;117(8):2358–65.CrossRefPubMed
2.
Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-inoue T, Akiyama H, et al. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. Bone Marrow Transplant. 2013;48(4):529–36.CrossRefPubMed
3.
Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–89.CrossRefPubMedPubMedCentral
4.
Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.CrossRefPubMedPubMedCentral
5.
6.
Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematol Am Soc Hematol Educ Progr. 2013;2013:220–6.CrossRef
7.
Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434–9.CrossRefPubMed
8.
Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007;110(4):1262–70.CrossRefPubMed
9.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21.CrossRefPubMedPubMedCentral
10.
Spiekermann K, Bagrintseva K, Schoch C, Haferlach T, Hiddemann W, Schnittger S. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood. 2002;100(9):3423–5.CrossRefPubMed
11.
Chatain N, Perera RC, Rossetti G, Rossa J, Carloni P, Schemionek M, et al. Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine. Leukemia. 2015;29(12):2434–8.CrossRefPubMed
12.
Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters–an analysis of 3082 patients. Blood. 2008;111(5):2527–37.CrossRefPubMed
13.
Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001;113(4):983–8.CrossRefPubMed
14.
Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–35.CrossRefPubMed
15.
Auewarakul CU, Sritana N, Limwongse C, Thongnoppakhun W, Yenchitsomanus PT. Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. Cancer Genet Cytogenet. 2005;162(2):127–34.CrossRefPubMed
16.
Rezaei N, Arandi N, Valibeigi B, Haghpanah S, Khansalar M, Ramzi M. FMS-like tyrosine kinase 3 (FLT3) and nucleophosmin 1 (NPM1) in Iranian adult acute myeloid leukemia patients with normal karyotypes: mutation status and clinical and laboratory characteristics. Turk J Haematol. 2017;34(4):300–6.PubMedPubMedCentral
17.
Elyamany G, Awad M, Fadalla K, Albalawi M, Al Shahrani M, Al AA. Frequency and prognostic relevance of FLT3 mutations in Saudi acute myeloid leukemia patients. Adv Hematol. 2014;2014:141360.PubMedPubMedCentral
18.
Ali A, Gale RE, Shakoori AR. Detection of FLT3/TKD and IDH1 mutations in Pakistani acute myeloid leukemia patients by denaturing HPLC. J Cell Biochem. 2017;118(5):1174–81.CrossRefPubMed
19.
Chou SC, Tang JL, Hou HA, Chou WC, Hu FC, Chen CY, et al. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. Leuk Res. 2014;38(11):1278–84.CrossRefPubMed
20.
Zaker F, Mohammadzadeh M, Mohammadi M. Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes. Arch Iran Med. 2010;13(1):21–5.PubMed
21.
Wang W, Wang XQ, Xu XP, Lin GW. Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group. J Int Med Res. 2010;38(2):432–42.CrossRefPubMed
22.
Gari M, Abuzenadah A, Chaudhary A, Al-Qahtani M, Banni H, Ahmad W, et al. Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis. Int J Mol Sci. 2008;9(11):2194–204.CrossRefPubMedPubMedCentral
23.
Eisfeld AK, Kohlschmidt J, Mrozek K, Blachly JS, Walker CJ, Nicolet D, et al. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia. 2018;32(6):1338–48.CrossRefPubMedPubMedCentral
24.
Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, et al. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017;1(5):331–40.CrossRefPubMedPubMedCentral
25.
Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, et al. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017;1(19):1546–50.CrossRefPubMedPubMedCentral
26.
Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111(3):1552–9.CrossRefPubMedPubMedCentral
27.
Perry M, Bertoli S, Rocher C, Hayette S, Ducastelle S, Barraco F, et al. FLT3-TKD mutations associated with NPM1 mutations define a favorable-risk group in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(12):e545–50.CrossRefPubMed
28.
Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, et al. Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia. PLoS One. 2014;9(3):e89560.CrossRefPubMedPubMedCentral
29.
Andersson A, Johansson B, Lassen C, Mitelman F, Billstrom R, Fioretos T. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol. 2004;72(5):307–13.CrossRefPubMed
30.
Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106(12):3747–54.CrossRefPubMed
31.
Moreno I, Martin G, Bolufer P, Barragán E, Rueda E, Román J, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica. 2003;88(1):19–24.PubMed
32.
Sheikhha MH, Awan A, Tobal K, Liu Yin JA. Prognostic significance of FLT3 ITD and D835 mutations in AML patients. Hematol J. 2003;4(1):41–6.CrossRefPubMed
33.
Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372–80.CrossRefPubMed
34.
Wakita S, Yamaguchi H, Omori I, Terada K, Ueda T, Manabe E, et al. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia. 2013;27(5):1044–52.CrossRefPubMed
35.
Wakita S, Yamaguchi H, Ueki T, Usuki K, Kurosawa S, Kobayashi Y, et al. Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. Leukemia. 2016;30(3):545–54.CrossRefPubMed
36.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.CrossRefPubMed
37.
Jahic A, Iljazovic E, Hasic S, Arnautovic AC, Sabitovic D, Mesanovic S, et al. Prognostic parameters of acute myeloid leukaemia at presentation. Med Arch. 2017;71(1):20–4.CrossRefPubMedPubMedCentral
38.
Wang L, Lin D, Zhang X, Chen S, Wang M, Wang J. Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. Leuk Res. 2005;29(12):1393–8.CrossRefPubMed
39.
Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18(8):1061–75.CrossRefPubMedPubMedCentral
Metadata
Title
Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia
Authors
Masahiro Sakaguchi
Hiroki Yamaguchi
Marika Kuboyama
Yuho Najima
Kensuke Usuki
Toshimitsu Ueki
Iekuni Oh
Shinichiro Mori
Eri Kawata
Nobuhiko Uoshima
Yutaka Kobayashi
Shinichi Kako
Kenji Tajika
Katsuhiro Shono
Kensuke Kayamori
Masao Hagihara
Junya Kanda
Hitoji Uchiyama
Junya Kuroda
Naoyuki Uchida
Yasushi Kubota
Shinya Kimura
Saiko Kurosawa
Kenta Date
Nana Nakajima
Atsushi Marumo
Ikuko Omori
Yusuke Fujiwara
Kazuki Terada
Shunsuke Yui
Satoshi Wakita
Kunihito Arai
Tomoaki Kitano
Kazuhiko Kakihana
Yoshinobu Kanda
Kazuteru Ohashi
Takahiro Fukuda
Koiti Inokuchi
Publication date
01-11-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02720-z

Other articles of this Issue 5/2019

International Journal of Hematology 5/2019 Go to the issue

Original Article

Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients

Original Article

A less-intensive anticoagulation protocol of therapeutic unfractionated heparin administration for pregnant patients

Case Report

A case of central nervous system graft-versus-host disease following allogeneic stem cell transplantation

Original Article

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Original Article

Study of pathophysiology and molecular characterization of congenital anemia in India using targeted next-generation sequencing approach

Original Article

Essential thrombocytosis attributed to JAK2-T875N germline mutation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits